AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02879981 — intervention group
Intervention type: DRUG
Intervention: Sulfamethoxazole
Description: Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
Study NCT02550444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Clonidine
Description: Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
Study NCT02550444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Clonidine
Description: Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
Study NCT02550444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
Study NCT00753948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Nitro L-arginine-methylester (L-NAME)
Description: A non-specific inhibitor of the nitric oxide synthase enzyme.
Study NCT00753948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-Nitro L-arginine-methylester (L-NAME)
Description: A non-specific inhibitor of the nitric oxide synthase enzyme.
Study NCT00753948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Nitro L-arginine-methylester (L-NAME)
Description: A non-specific inhibitor of the nitric oxide synthase enzyme.
Study NCT02257749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Description: The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.
Study NCT02257749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Education Intervention (Standard Care)
Description: An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
Study NCT02257749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Education Intervention (Standard Care)
Description: An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
Study NCT01847092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD1722
Study NCT01847092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for AZD1722
Study NCT00185237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menostar (estradiol transdermal delivery system)
Description: Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
Study NCT00185237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch
Study NCT00825994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Description: 2 g omega-3 fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), PO \[by mouth\], qd \[every day\]
Study NCT02409433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.~The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.
Study NCT02409433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin
Description: the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
Study NCT00592631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP-Continuous Positive Airway Pressure
Description: Cpap will be worn at night by subjects 6 to 7 days duration.
Study NCT00592631 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: SHAM will be worn at night by subjects 6 to 7 days duration.
Study NCT04106544 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational Procedures
Description: The investigational assessments will be performed
Study NCT04751227 — intervention group
Intervention type: DRUG
Intervention: Modafinil
Description: 100-200 mg oral daily for for Wakefulness in the Critical Care Units
Study NCT00878592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and life style modification
Description: This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (\<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of \~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
Study NCT02879981 — intervention group
Intervention type: DRUG
Intervention: Trimethoprim
Description: Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
Study NCT05384366 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Neoadjuvant chemotherapy
Description: doublet of taxane and carboplatin
Study NCT01915459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A(Botulax®)
Description: IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone
Study NCT01915459 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A(Botox®)
Study NCT04860401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of tissue oxygenation with novel diagnostic near-infrared spectroscopy device (OxyPrem) (no clinical decisions based on oxygenation levels)
Description: The precision of OxyPrem is assessed by repeated measurements of tissue oxygenation and hemoglobin concentration. The accuracy of OxyPrem is assessed by comparing the measurement data to those acquired simultaneously by established NIRS devices and standard clinical monitoring devices. In substudy 1, healthy adult subjects are enrolled, in substudy 2, measurements are conducted on preterm neonates.
Study NCT01794858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
Study NCT02919449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-NIS
Description: This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
Study NCT02919449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered every 3 weeks
Study NCT02451540 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: HRCT scan
Description: HRCT scan of thorax, at baseline and after 3 months
Study NCT02451540 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HRCT scan
Description: HRCT scan of thorax, at baseline and after 3 months
Study NCT02451540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Roflumilast
Description: Placebo, once a day in the morning during 3 months
Study NCT02451540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Roflumilast, once a day in the morning during 3 months
Study NCT01425229 — intervention group
Intervention type: DRUG
Intervention: Bosentan
Description: * Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~* Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14
Study NCT02248857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UMS Strategy
Description: Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
Study NCT02248857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Texting Reminders
Description: In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
Study NCT00809068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate and tibolone
Description: fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
Study NCT00809068 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: tibolone
Description: tibolone 2.5 mg daily 23 weeks
Study NCT02040831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV LID ΔM2-2 Vaccine
Description: 10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
Study NCT02040831 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
Study NCT02799875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher permissive hypercapnia
Description: * pCO2 ≥ 60mmHg with an upper limit ≤ 75mmHg;~* pH ≥ 7.20 from a capillary or arterial blood sample;
Study NCT02799875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Permissive Hypercapnia
Description: * pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg;~* pH ≥ 7.25 from a capillary or arterial blood sample;
Study NCT02631291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral self-monitoring
Description: Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.
Study NCT02631291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral self-monitoring + Motivational interviewing
Description: Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
Study NCT02927730 — intervention group
Intervention type: OTHER
Intervention: no interventions
Description: no interventions
Study NCT01154491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection.
Study NCT01154491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Erythropoetin: 40,000 units subcutaneous (unique dose).
Study NCT01154491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection.
Study NCT00410189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: 300 mg by mouth daily for 28 Days.
Study NCT03729635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral-intercostal fascial plane block (PIFB)
Description: Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
Study NCT00443118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece resuscitator Neopuff TM
Description: Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
Study NCT00443118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self Inflating Bag with PEEP
Description: Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
Study NCT00443118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self Inflating Bag without PEEP
Description: Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
Study NCT01590368 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed electrode
Description: 12 electrodes will be placed on the subject for an ECG reading to be taken
Study NCT01590368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified test electrode
Description: 12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
Study NCT01196897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN LAA Closure Technology (Gen 4.0)
Description: Implantation of the WATCHMAN device into the left atrial appendage.
Study NCT03349255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous ET1402L1-CART cells
Description: Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct
Study NCT01051037 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: 3 fraction of stereotactic body radiation therapy within 10 days.
Study NCT01051037 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
Study NCT01033084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
Study NCT01033084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Patient will receive sertraline 50mg/day.
Study NCT01033084 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: double placebo
Description: double placebo arm (sham stimulation/placebo pill)
Study NCT01864083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Study NCT01864083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)
Study NCT01864083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission mammography (PEM) When available
Study NCT01864083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR
Study NCT05544435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational İnterviewing
Description: Motivational Interviewing (MI), which is one of these methods, is an individual-based counselling approach that can easily be used by nurses who have been trained to help the management of disease in chronic diseases (Berhe et al., 2020; Kızılırmak \& Demir, 2018; Maslakpak et al., 2020). The core principles of MI includes expressing empathy by providing acceptance and understanding, realizing inconsistencies, avoiding discussions and supporting self-efficacy (Matinolli et al., 2012). The main purpose of MI is to identify the ambivalent emotions that occur in the patient in health-related activities, to strengthen and encourage insights of patients by supporting healthy lifestyle changes and self-confidence (R.Miller \& Rollnick, 2013). Because of its flexibility and ability to be applied in different behavioural aspects, MI can be administered individually and in groups by trained individuals (Maslakpak et al., 2020).
Study NCT02910141 — intervention group
Intervention type: DEVICE
Intervention: Continuous subcutaneous insulin infusion
Description: Infusion of short-acting insulin from a portable pump
Study NCT03100448 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: On1 Concept
Description: NobelActive implant placement with simultaneous On1 Base placement
Study NCT03674658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propafenone
Description: oral, TID
Study NCT03674658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propafenone
Description: oral, TID
Study NCT00393029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes
Description: Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
Study NCT04101734 — intervention group
Intervention type: DEVICE
Intervention: Double Lumen Endotracheal Tube.
Description: Intubation was performed with Double Lumen Endotracheal Tube.
Study NCT04101734 — intervention group
Intervention type: DEVICE
Intervention: Double Lumen Video Endotracheal Tube.
Description: Intubation was performed with Double Lumen Video Endotracheal Tube.
Study NCT04086602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IZD334
Description: Active Drug
Study NCT04086602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo to Match
Study NCT00610285 — intervention group
Intervention type: OTHER
Intervention: Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)
Description: Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
Study NCT04152148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 500mg BAT4306F
Description: Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
Study NCT04152148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 750mg BAT4306F
Description: Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
Study NCT04152148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 900mg BAT4306F
Description: Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
Study NCT04152148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1000mg BAT4306F
Description: Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
Study NCT02622477 — intervention group
Intervention type: DRUG
Intervention: Pirfenidone
Description: This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
Study NCT02566811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal surgery
Description: Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
Study NCT01383187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DE graft and PRP concentrate
Description: Application of DE graft together with PRP concentrate
Study NCT01383187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DE graft
Description: DE grafting presents a standard treatment method in patients with deep-burn trauma.
Study NCT02566811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal surgery
Description: Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
Study NCT02566811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Bilateral pelvic and para-aortic lymph node dissection
Study NCT01786681 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive pressure
Study NCT00506779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Phase I = Maximum tolerated dose (MTD) derived from dose escalation of 400, 500, 600 mg by mouth daily